Background: Desmoplastic small round cell tumor (DSRCT) and synovial sarcoma are rare tumors with dismal outcomes requiring new therapeutic strategies. Immunotherapies have shown promise in several cancer types, but have not been evaluated in DSRCT and synovial sarcoma.
INTRODUCTION
Desmoplastic small round cell tumor (DSRCT) and synovial sarcoma are aggressive and rare cancers. DSRCT is a soft-tissue sarcoma that primarily occurs in the abdomen and mainly affects adolescents with a male predominance. Survival rates are extremely poor with 5-year overall survival of 15%. 1 
,2 Standard treatment for DSRCT consists
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Survival outcomes are also poor with a 10-year overall survival rate of 50% and half of patients developing metastasis within 5 years of diagnosis, primarily to the lung or pleura. 3, 4 Other than surgery for localized disease, conventional treatments such as chemotherapy and radiotherapy have not had significant impacts on outcomes. Due to the current limitations in treatment for DSRCT and synovial sarcoma, there is a need to find new therapeutic options.
Immunotherapies have shown promise in numerous cancer types with FDA approval of immune checkpoint inhibitors for recurrent Hodgkin's lymphoma, non-small cell lung cancer, metastatic renal cell carcinoma, and melanoma. [5] [6] [7] [8] [9] Within the pediatric population, the FDA approval of anti-GD2 antibodies for neuroblastoma and anti-CD19 chimeric antigen receptor T cells for the treatment of relapsed acute lymphoblastic B cell leukemia suggests immune therapy can also be important for children. 10, 11 As immunotherapy options show increasingly more significant and durable responses, there are still many unanswered questions. Despite much research, no reliable biomarker has been found to indicate whether a patient will respond to these therapies. Checkpoint inhibition successes have shown that there is an association of high expression of programmed cell death ligand 1 (PD-L1) with poor prognosis; however, it did not predict therapeutic benefit from cognate inhibitors. [12] [13] [14] [15] [16] There have been a number of studies detailing the expression of PD-L1 and PD-1 on numerous sarcoma subtypes, including DSRCT and synovial sarcoma. Most of these studies show conflicting data on expression levels and clinical outcomes. [17] [18] [19] [20] Whether immunotherapies for DSRCT and synovial sarcoma will be useful is currently unknown. Numerous results from other cancer subtypes suggest that expression of relevant immunologic molecules and intratumoral immune cell infiltrates may be predictive of prognosis and therapeutic response. [20] [21] [22] [23] [24] [25] In order to explore which immunotherapies may be useful for patients with DSRCT and synovial sarcoma, we sought to describe the immunologic profiles of specimens from each tumor type. We characterized tumoral expression of human leukocyte antigen (HLA)-A/-B/-C and -2-microglobulin (B2M) and calculated a "cytotoxic T-lymphocyte (CTL) target score." 26 We also assessed tumoral PD-L1 expression and the presence of intratumoral CD4 + , CD8 + , FOXP3 + , CD45RO + , and CD56 + lymphocytes via immunohistochemistry (IHC). Our data suggest that immune profiling of DSRCT and synovial sarcoma may aid in the selection of which type of immunotherapy may be most useful for these patients.
METHODS

Tissue microarray construction
The Institutional Review Board at Nationwide Children's Hospital approved this study. Nine DSRCT and 12 synovial sarcoma samples were obtained through the Nationwide Children's Hospital Pathology Department. Three of the nine DSRCT samples were collected at diagnosis with each sample from a different patient while the other five samples were collected at recurrence with three different patients represented. One DSRCT sample was not analyzed with the other samples when separated in to diagnosis or recurrence categories as there was no documentation about when in the treatment time course the sample was obtained. Nine of the 12 synovial sarcoma samples were collected at diagnosis with 6 different patients represented while the other 3 samples were collected at recurrence representing 2 patients. One occurrence of the same patient having samples from diagnosis and through relapse with synovial sarcoma. These samples were included onto tissue microarrays constructed from 2 mm punches of formalin-fixed paraffin-embedded tissue blocks.
Immunohistochemical staining
All stages of the IHC procedure were automated on the Bond III IHC system (Leica Microsystems) using the Refine polymer detection system, with 3,3 ′ -diaminobenzidine visualization and counterstain with hematoxylin.
We used an antibody to HLA class I ABC (clone EMR8-5, Abcam Inc, catalog number ab70328) at a dilution factor of 1:6,000, after on- to 100%), as previously described. 21 
Calculation of CTL target scores
For tumor samples where HLA-A/B/C and B2M expression were detected by immunohistochemical staining, we calculated CTL target scores as previously described 21 : average HLA-A/B/C score (range, 0-300) = % positive staining × staining intensity/n. Average B2M score (range, 0-300) = % positive staining × staining intensity/n. CTL target score (range, 0-900) = average HLA score × average B2M score/100. 
Scoring of CD4
Statistical analyses
All statistical analyses were performed using GraphPad Prism, version 7 (GraphPad Software, La Jolla, California). Tumor subtype immunohistochemical staining scores and cellular infiltrates were compared using Mann-Whitney nonparametric tests. Results were considered to be significant when P ≤ 0.05. 
RESULTS
Recurrent DSRCT and synovial sarcoma show decreased HLA scores and CTL target scores compared to diagnostic samples
To assess the tumor immune infiltrates, we performed immunohistochemical staining for immunologic markers of interest (HLA-A/B/C, B2M, and PD-L1) on patient DSRCT and synovial sarcoma samples. We scored their staining intensity and percentage as previously described. 21 In general, synovial sarcoma and DSRCT displayed greater median HLA-A/B/C staining ( Figure 1A ) and CTL target scores ( Figure 1B) at diagnosis than at recurrence. For synovial sarcoma, B2M scores decreased from diagnosis to recurrence, whereas DSRCT B2M scores increased from diagnosis to recurrence ( Figure 1C ).
DSRCT and synovial sarcoma exhibit low PD-L1 expression
To further assess the potential for CTL inhibition, we assessed tumoral PD-L1 expression. Both DSRCT and synovial sarcoma had minimally positive PD-L1 scores at diagnosis. Both tumor types showed a decrease in PD-L1 scores in the recurrence samples compared with diagnostic samples (Figure 1D ).
Synovial sarcoma has high CTL scores compared with DSRCT
We previously reported a CTL target score that takes into account both HLA class I and B2M expression to predict which tumors might be susceptible to CTLs. 21 We found synovial sarcoma displayed a greater median HLA-A/B/C, B2M, and thus greater CTL target scores at diagnosis and recurrence compared with DSRCT. Utilizing Mann-Whitney test, there was a statically significant difference between HLA scores and CTL scores comparing DSRCT to synovial sarcoma (Supplementary Information Table S1 ).
Low HLA scores with increase in CD56 + demonstrated in DSRCT
We quantified CD8 + , CD4 + , FOXP3 + , CD45RO + , and CD56 + lymphocytes within the tumors. We found that DSRCT had an increased CD8 + , and thus total tumor-infiltrating T cells, than synovial sarcoma at diagnosis. However, at recurrence, DSRCT had fewer T-cell numbers than synovial sarcoma (Figure 2A-B) . DSRCT showed an increase in CD56 + cells from diagnosis to recurrence (Figure 2A ).
Immunologic marker staining scores do not correlate with cellular infiltrates
We used Spearman correlation coefficients to determine whether the expression of immunologic cells correlated with each other or the lymphocytic cellular infiltrates we observed in the tumors. The only "very strong" correlation we found was a positive correlation between the HLA expression and the CD8 + T-cell infiltrates (r = 0.81, P = 0.002) and a "strong" with B2M (r = 0.78, P = 0.003) in synovial sarcoma (Figure 3A) . We also observed HLA expression and CTL target score correlated "strongly" with CD45RO + infiltrates (r = 0.74, P = 0.007; r = 0.61, P = 0.04, respectively), likely reflective of the increase in CD8 + T cells.
The only correlation seen in the DSRCT tumors was a "strong" correlation between HLA scoring and the presence of CD4 + cells (r = 0.70, P = 0.04) (Figure 3A-D) . We did not detect any correlations for synovial sarcoma or DSRCT with PD-L1 ( Figure 3D ).
Cellular infiltrates correlate with other cellular infiltrates in synovial sarcoma
We performed Spearman correlation calculations to determine whether intratumoral lymphocytic cellular infiltrates correlated with other lymphocytic cellular infiltrate types. In DSRCT, we did not detect any significant correlations ( Figure 4A) . In synovial sarcoma, we observed a "very strong" positive correlation between CD45RO + infiltrates with both CD8 + (r = 0.87, P < 0.001) and CD4 + (r = 0.85, P < 0.001) ( Figure 4B ), which likely represent memory CD8 + and CD4 + infiltrates. We also observed a "strong" positive correlation between Foxp3 + infiltrates and CD4 + cells (r = 0.70, P = 0.015), representing T regulatory cells. We also observed a "very strong" correlation between CD8 + and CD4 + infiltrates (r = 0.88, P < 0.001), which is likely indicative of a strong Th1 immune environment. 
Evaluation of immunologic marker expression and immune cellular infiltrates in synovial sarcoma tumors from the same patient reveals that immunosuppressive infiltrates progressed with each relapse accompanied by wide tumor heterogeneity
We assessed a few tumor samples obtained from the same patient with synovial sarcoma beginning at diagnosis and through two recurrences.
We had two samples from the patient's initial diagnosis at 18 years of age followed by one sample from lung recurrences 3 years and 4 years after diagnosis. The patient received chemotherapy and radiation after diagnosis. We observed a decrease in HLA, B2M, and CTL target scores ( Figure 5A-C) from diagnosis to relapse. At first relapse, the PD-L1 score increased by 4.5-fold, but by the patient's second relapse, tumoral PD-L1 expression was no longer present ( Figure 5D ). CD8 + cells, CD4 + cells, total T cells, and CD45RO + cells all decreased with each relapse (Figure 6 ). Also, CD56 + lymphocytic infiltrates initially decreased in the first relapse, but then increased dramatically in the second relapse ( Figure 6 ).
DISCUSSION
Here, we describe cellular immune profiles of a cohort of human DSRCT and synovial sarcoma tissue samples. We included specimens at diagnosis and, when available, at relapse. We calculated the CTL target score, which takes into account both HLA-A/B/C and B2M expression, as both are vital components for functional antigen Exactly what biomarkers predict response to immunotherapies is not well defined, but most likely there will be numerous parameters that in combination will be predictive. For example, Galon et al. described the combination of CD8 + cellular infiltrates and CD45RO + cellular infiltrates to formulate a prognostically significant "immunoscore" in colon cancer. 27 In fact, naturally occurring tumorinfiltrating lymphocytes have been associated with better patient survival in numerous cancer types [28] [29] [30] and may also correlate with better responsiveness to checkpoint inhibition. 31 In addition, predictive biomarkers of response are likely to depend on the type of immunotherapy used. MHC class I expression is important for antigen presentation, necessitating its consideration when planning for use of strategies which target neoantigens. Immunotherapies that require MHC class I expression on target cells for recognition include autologous T-cell transfer with or without genetically modified T-cell receptors, adoptively transferred T cells such as donor lymphocyte infusions, use of immune checkpoint inhibitors, and tumor vaccines. 26 We found that CTL target scores in our synovial sarcoma samples were significantly higher than in those from DSRCT. Thus, synovial sarcoma may be a particularly suitable candidate for CTLbased immunotherapeutics at diagnosis, but as we found decreasing CTL target scores in recurrence, these strategies may be less beneficial at relapse. Despite synovial sarcoma demonstrating a higher CTL target score compared with DSRCT, neither tumor type has a high target score to begin with. Whether the lower scores in synovial cell sarcoma are sufficient to enable neoantigen presentation is unknown. In this regard, it is interesting to note that NY-ESO-1, a cancer-testis antigen expressed on 80% of all synovial sarcomas, is being explored as a therapeutic CTL target. 32 Alternatively, some immunotherapeutic approaches do not rely on neoantigen presentation by MHC class I such as chimeric antigen receptor T cells, bispecific T-cell engagers, and NK cell therapies.
Given the low CTL target scores for both tumor types at relapse, we increased CD56 + cells intratumorally is a poor prognostic sign. [33] [34] [35] Numerous studies have evaluated the expression of PD-L1 in DSRCT and synovial sarcoma with conflicting results. While some authors reported high levels of PD-L1 in DSRCT tissue 20, 36 and in synovial sarcoma, 18 in contrast, and consistent with our findings, two other groups reported very low or no expression of PD-L1 in either tumor type. 19, 37 We observed extensive heterogeneity of PD-L1 expression within each tumor type, which might explain the disparate reports. Despite an association between high PD-L1 expression and poor prognosis in other cancers, PD-L1 expression has not accurately predicted outcomes following PD-1 or PD-L1 blockade therapies. [12] [13] [14] [15] [16] We were unable to determine prognostic value of tumoral PD-L1 expression due to our small sample size.
In one synovial sarcoma patient, we tested multiple tumor tissue samples during different treatment stages. Over the course of two relapses, the intratumoral cellular infiltrates appeared to be different each time. This observation is consistent with other published reports of the immune infiltrates shifting through treatment and relapse. 38, 39 From this one patient as well as looking at all our samples, we can conclude that a possible challenge for immunotherapies to be efficacious is heterogeneity not only within the same tumor in one patient but also the generalizability of findings to other patient's tumors. The two diagnostic samples of our one patient revealed a wide range among many of the cellular infiltrates (Figure 6 ), demonstrating that even within the same tumor, there is a potential the entire tumor may not respond uniformly to immunotherapies. Whether tumor heterogeneity is a significant challenge, whether therapies can cause tumors to become more homogeneous, or whether therapies can overcome this heterogeneity is still unknown.
Both synovial cell sarcoma and DSRCT have unacceptably poor outcomes. Our findings suggest immunotherapies may be promising, albeit strategies may need to differ at diagnosis with CTL-based therapies compared with relapse which perhaps need non-CTL-based therapies.
Our conclusions are limited by small sample size, but the wide heterogeneity and case-to-case variability we observed even in these few cases suggest the need to develop and validate predictive biomarkers for individual patients. Indeed, patient-specific immune scoring using IHC may enable rational selection of immunotherapeutic treatments which could be tested in a clinical trial. Such biomarkers will have utility for more personalized medicine and, hopefully, better patient outcomes.
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